# A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

> **NCT04448223** · PHASE2 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 100 (estimated)

## Conditions studied

- Primary Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** CKD-351
- **DRUG:** Latanoprost+Dorzolmamide

## Key facts

- **NCT ID:** NCT04448223
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-11
- **Primary completion:** 2022-12-05
- **Final completion:** 2022-12-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04448223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04448223, "A Clinical Study to Evaluate the Efficacy and Safety of CKD-351". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04448223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*